These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18157712)

  • 1. Arterial thrombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke?
    Girolami A; Tezza F; Allemand E; Girolami B
    J Thromb Thrombolysis; 2008 Oct; 26(2):163-4. PubMed ID: 18157712
    [No Abstract]   [Full Text] [Related]  

  • 2. Drospirenone-containing oral contraceptives and risk of adverse outcomes after myocardial infarction.
    Karabay CY; Kocabay G; Oduncu V; Kalayci A; Guler A; Karagöz A; Candan O; Basaran O; Zehir R; Izgi A; Esen AM; Kırma C
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):387-93. PubMed ID: 23361975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on "Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review".
    Cameron S
    BJOG; 2013 Jun; 120(7):811. PubMed ID: 23802311
    [No Abstract]   [Full Text] [Related]  

  • 4. Pregnancy is more dangerous than the pill: A critical analysis of professional responses to the Yaz/Yasmin controversy.
    Geampana A
    Soc Sci Med; 2016 Oct; 166():9-16. PubMed ID: 27522113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myocardial infarction associated with Yasmin oral contraceptive.
    Ortí G; Mira Y; Vaya A
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):336-7. PubMed ID: 17636199
    [No Abstract]   [Full Text] [Related]  

  • 6. Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review.
    Wu CQ; Grandi SM; Filion KB; Abenhaim HA; Joseph L; Eisenberg MJ
    BJOG; 2013 Jun; 120(7):801-10. PubMed ID: 23530659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sinus thrombosis in a healthy female taking oral contraceptives].
    Mogensen SS; Abild-Nielsen A; Bjarnason NH
    Ugeskr Laeger; 2011 Sep; 173(39):2422-3. PubMed ID: 21958487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drospirenone-containing oral contraceptives may increase the risk of venous thromboembolism.
    Jick SS
    Evid Based Nurs; 2014 Jul; 17(3):71. PubMed ID: 24170817
    [No Abstract]   [Full Text] [Related]  

  • 9. The safety profile of Yasmin is similar to other combined oral contraceptives.
    Cronin M; Korner P
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):245-6. PubMed ID: 18372279
    [No Abstract]   [Full Text] [Related]  

  • 10. Drospirenone: more cases of thrombosis than with levonorgestrel.
    Prescrire Int; 2013 Nov; 22(143):267. PubMed ID: 24427839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N; Smith KP
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yasmin and venous thromboembolism: new case reports.
    López M; Vayá A; Martínez Triguero ML; Contreras MT; Todolí J; Ricart A; Laiz B
    Clin Hemorheol Microcirc; 2009; 42(1):65-9. PubMed ID: 19363241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?
    Han L; Jensen JT
    Obstet Gynecol Clin North Am; 2015 Dec; 42(4):683-98. PubMed ID: 26598309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Images in Vascular Medicine. A downward dog seldom bites: A rare case of bilateral ulnar artery thrombosis from yoga.
    Kim LN; Sammel AM
    Vasc Med; 2020 Aug; 25(4):383-384. PubMed ID: 32407188
    [No Abstract]   [Full Text] [Related]  

  • 15. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update.
    Reid R;
    J Obstet Gynaecol Can; 2010 Dec; 32(12):1192-1197. PubMed ID: 21176332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contraceptive hormones, vascular risk and abnormal precipitation of serum gamma-globulins (author's transl)].
    Beaumont V; Lemort N; Lorenzelli L; Mosser A; Beaumont JL
    Pathol Biol (Paris); 1978 Dec; 26(9-10):531-7. PubMed ID: 85291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal central artery occlusion in a young woman after ten days of a drospirenone-containing oral contraceptive (Yasmin).
    Girolami A; Vettore S; Tezza F; Girolami B
    Thromb Haemost; 2007 Aug; 98(2):473-4. PubMed ID: 17721635
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective.
    Raymond EG; Burke AE; Espey E
    Obstet Gynecol; 2012 May; 119(5):1039-44. PubMed ID: 22525916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.